Physician profile
Lisa D Hooker
NPI 1568766145
$2,196.80
in general payments reported to CMS, 2019-2025
26 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $609 · 2022: $535 · 2023: $327 · 2024: $341 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $282.28 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $250.81 | 2021-2023 | Myrbetriq |
| Myovant Sciences INC. | $233.82 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $212.01 | 2021-2022 | |
| Janssen Biotech, INC. | $171.76 | 2021-2025 | Erleada, Akeega, Balversa |
| Abbvie INC. | $165.24 | 2021-2025 | |
| Endo USA, INC. | $89.17 | 2024-2025 | Xiaflex |
| Rochester Medical Corporation | $87.17 | 2021 | |
| Coloplast Corp | $85.90 | 2021-2025 | Speedicath |
| Myriad Genetic Laboratories, INC. | $75.41 | 2024 | Prolaris |
| Dendreon Pharmaceuticals LLC | $67.42 | 2022-2025 | Provenge |
| 180 Medical, INC. | $66.92 | 2023-2025 | Gentlecath |
| Urogen Pharma, INC. | $57.61 | 2021-2025 | |
| Medtronic, INC. | $50.35 | 2021 | |
| Pfizer INC. | $45.85 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $37.09 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $27.93 | 2022-2023 | Spaceoar Vue System - 10ml |
| Urovant Sciences INC | $27.93 | 2022 | |
| Olympus America INC. | $24.56 | 2025 | Itind System |
| Merck Sharp & Dohme LLC | $22.32 | 2025 | Welireg, Keytruda |
| Teleflex LLC | $21.60 | 2025 | Barrigel |
| Tempus Ai, INC | $21.04 | 2024 | |
| Immunitybio, INC. | $19.91 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $19.03 | 2025 | |
| Blue Earth Diagnostics | $18.62 | 2021 | |
| Axonics, INC. | $15.05 | 2023 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.